Early picc-line infections in non-neutropenic patients are mainly due to E. coli suggesting that third-generation cephalosporin may be used as a first-line antibiotic therapy - 29/02/24
Highlights |
• | Among Gram-negative bacilli CLABSI, E. coli identification was the more frequent. |
• | Among Gram-negative bacilli CLABSI, E. coli identification happened earlier after insertion. |
• | Third-generation cephalosporin may be used as a first-line antibiotic therapy among non-neutropenic patients. |
Abstract |
Purpose |
To describe the rate of peripherally inserted central catheter (PICC) -associated bloodstream infections, and the pathogens involved.
Methods |
We prospectively analyzed data collected from all adult patients with a PICC insertion in a hematology unit in a tertiary care center between January 1, 2017 and June 30, 2020.
Results |
A total of 370 PICCs were inserted in 275 patients with hematological malignancies: 54 (15 %) confirmed cases of central-line associated bloodstream infection (CLABSI) were identified. Enterobacteria were the most frequent bacteria identified, involved in 35 % of CLABSIs. Group 1 enterobacteria bacteremia occurred a much shorter time after insertion (median time to CLABSI 16 days) than group 2 or group 3 enterobacteria (median time to CLABSI 64 days, p-value = 0.049).
Conclusion |
Among Gram-negative bacilli CLABSI among non-neutropenic patients, E. coli identification was the most frequent and occurred earlier after insertion, suggesting that third-generation cephalosporin may be used as a first-line antibiotic therapy for enterobacteria bacteremia among non-neutropenic patients.
Le texte complet de cet article est disponible en PDF.Keywords : Hematological malignancies, PICC, CLABSI, Thrombosis, Antibiotic therapy
Plan
Vol 54 - N° 2
Article 104842- mars 2024 Retour au numéro
Article précédent
- Clinical features and outcomes in adults with COVID-19 during the pre-Omicron and Omicron waves
- M. Martinot, A. Schieber, J.C. Ongagna, A. Henric, M. Eyriey, M. Mohseni-Zadeh, C. Ion, K demesmay, S. Gravier, C. Kempf
- Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France
- A. Saade, B. Wyplosz, M. Baldeyrou, C. Paris, P. Tattevin, C. Janssen, for the SPILF group “Vaccination et Prévention”
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?